In the present analysis, the use of SGLT2i dapagliflozin for 12 months in patients with HF and DM was associated with a decrease in troponin and BNP compared to the control group, as well as a reduction in left ventricular (LVESVi and LVEDVi) and left atrial (LAVi) volumes. This evidence concerns the gene NPPB and diabetes mellitus.